About LCA-Vision (NASDAQ:LCAV)
LCA-Vision Inc. is a provider of fixed-site laser vision correction services at its LasikPlus vision centers. The Company's vision centers provide the staff, facilities, equipment and support services for performing laser vision correction that employ advanced laser technologies to help correct nearsightedness, farsightedness and astigmatism. The Company's vision centers are supported by independent, ophthalmologists and credentialed optometrists, as well as other healthcare professionals. The ophthalmologists perform the laser vision correction procedures in the Company's vision centers, and ophthalmologists or optometrists conduct pre-procedure evaluations and post-operative follow-up care in-center. Most of the Company's patients receive a procedure called laser-assisted in situ keratomileusis (LASIK). As of December 31, 2011, it had performed over 1.2 million laser vision correction procedures in its vision centers in the United States and Canada.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
LCA-Vision (NASDAQ:LCAV) Frequently Asked Questions
What is LCA-Vision's stock symbol?
LCA-Vision trades on the NASDAQ under the ticker symbol "LCAV."
How were LCA-Vision's earnings last quarter?
LCA-Vision Inc. (NASDAQ:LCAV) posted its earnings results on Wednesday, April, 30th. The healthcare company reported ($0.01) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.23 by $0.24. The healthcare company had revenue of $25.53 million for the quarter, compared to analyst estimates of $32.04 million. View LCA-Vision's Earnings History.
Who are some of LCA-Vision's key competitors?
Some companies that are related to LCA-Vision include Johnson & Johnson (JNJ), Novartis (NVS), UnitedHealth Group (UNH), Pfizer (PFE), Roche (ROG), Merck & Co., Inc. (MRK), AbbVie (ABBV), Amgen (AMGN), Novo Nordisk A/S (NVO), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT), Eli Lilly and (LLY), Sanofi (SAN), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bayer (BAYN) and Thermo Fisher Scientific (TMO).
How do I buy LCA-Vision stock?
Shares of LCA-Vision can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact LCA-Vision?
LCA-Vision's mailing address is 7840 Montgomery Rd, CINCINNATI, OH 45236-4301, United States. The healthcare company can be reached via phone at +1-513-7929292.
MarketBeat Community Rating for LCA-Vision (LCAV)MarketBeat's community ratings are surveys of what our community members think about LCA-Vision and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
LCA-Vision (NASDAQ:LCAV) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
LCA-Vision (NASDAQ:LCAV) Earnings History and Estimates Chart
LCA-Vision (NASDAQ LCAV) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/30/2014||Q1 2014||$0.23||($0.01)||$32.04 million||$25.53 million||View||N/A|
|2/18/2014||Q4||($0.08)||($0.08)||$20.55 million||$20.60 million||View||Listen|
|7/30/2013||Q2 2013||($0.11)||$0.02||$23.00 million||$22.60 million||View||Listen|
LCA-Vision (NASDAQ:LCAV) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for LCA-Vision (NASDAQ:LCAV)
No dividend announcements for this company have been tracked by MarketBeat.com
LCA-Vision (NASDAQ LCAV) Insider Trading and Institutional Ownership History
LCA-Vision (NASDAQ LCAV) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/14/2013||Michael J Celebrezze||CEO||Buy||3,450||$2.90||$10,005.00|| |
|2/28/2013||Amy F Kappen||CFO||Buy||1,023||$3.00||$3,069.00|| |
LCA-Vision (NASDAQ LCAV) News Headlines
LCA-Vision (NASDAQ:LCAV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
LCA-Vision (NASDAQ:LCAV) Income Statement, Balance Sheet and Cash Flow Statement
LCA-Vision (NASDAQ LCAV) Stock Chart for Tuesday, January, 16, 2018